TTX101 for Malignant Gliomas (Including Glioblastoma!) Earns Orphan Drug Designation
Unsplash: https://unsplash.com/photos/58Z17lnVS4U

TTX101 for Malignant Gliomas (Including Glioblastoma!) Earns Orphan Drug Designation

  Right now, there is an urgent need to identify and develop treatments for people with malignant gliomas, including glioblastoma. Unfortunately, there are limited effective treatment options; these cancers are…

Continue Reading TTX101 for Malignant Gliomas (Including Glioblastoma!) Earns Orphan Drug Designation
ASCO 2023: Vorasidenib Hailed As “Unprecedented Improvement” in Glioma Treatment
source: pixabay.com

ASCO 2023: Vorasidenib Hailed As “Unprecedented Improvement” in Glioma Treatment

  At ASCO’s 2023 convention for patients diagnosed with glioma and a specific genetic alteration, Servier Pharmaceuticals announced that vorasidenib, the drug being investigated in its Phase III trial (INDIGO)…

Continue Reading ASCO 2023: Vorasidenib Hailed As “Unprecedented Improvement” in Glioma Treatment
DAY101 for pLGG Granted Rare Pediatric Disease Status
source: pixabay.com

DAY101 for pLGG Granted Rare Pediatric Disease Status

According to a July 27 news release from biopharmaceutical company Day One Biopharmaceuticals ("Day One"), the company's therapeutic option DAY101 received Rare Pediatric Disease designation within the United States. Altogether,…

Continue Reading DAY101 for pLGG Granted Rare Pediatric Disease Status
Zotiraciclib, a New Treatment for Glioma, is Granted Orphan Drug Designation
Source: Pixabay.com

Zotiraciclib, a New Treatment for Glioma, is Granted Orphan Drug Designation

  The European Organization for Research and Treatment of Cancer (EORTC) has been evaluating zotiraciclib, which is a new treatment for glioma. This drug has recently been granted the Orphan…

Continue Reading Zotiraciclib, a New Treatment for Glioma, is Granted Orphan Drug Designation
PointR Data Merges into Mateon Therapeutics — Company Will Focus on Using Data Analysis and AI to Develop New Treatments
https://pixabay.com/en/notebook-work-girl-computer-woman-2386034/

PointR Data Merges into Mateon Therapeutics — Company Will Focus on Using Data Analysis and AI to Develop New Treatments

According to a press release from Mateon Therapeutics, Mateon's recent merger agreement with PointR Data establishes plans to combine the use of artificial intelligence and data collection for the development…

Continue Reading PointR Data Merges into Mateon Therapeutics — Company Will Focus on Using Data Analysis and AI to Develop New Treatments